In these and other haematological malignancies, vaccines that prime and/or boost tumor‐specific CD8+ T cells are attractive therapeutic options to prevent or delay disease progression, especially in the setting of minimal residual disease (MRD).1, 2. Here, CD8A is linked to neoplasm.